Valuation: Vectura Group

Market Cap 100.46Cr 88Cr 81Cr 75Cr 141.24Cr 9.69TCr 143.51Cr 973.23Cr 381.51Cr 4.74TCr 377.23Cr 369Cr 16TCr P/E 2019
-27.3x
P/E 2020 6.2x
Enterprise Value 93Cr 82Cr 75Cr 69Cr 130.78Cr 8.97TCr 132.88Cr 901.15Cr 353.25Cr 4.39TCr 349.29Cr 341.67Cr 15TCr EV / Sales 2019
2.8x
EV / Sales 2020 3.49x
Free-Float
-
Yield 2019 *
-
Yield 2020 -
31/25/31 Liquidia Technologies, Inc. Enters into an Exclusive Licensing Agreement with Vectura Limited CI
17/24/17 Molex Asia Holdings Ltd. signed an agreement to acquire Vectura Group plc from Vectura Fertin Pharma, Inc. for £300 million. CI
16/24/16 Mundipharma and Vectura Announce Plans to Reformulate Fluticasone Propionate/Formoterol Fumarate CI
29/21/29 EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation CI
03/21/03 Philip Morris CEO does not need M&A to hit smoke free goals RE
02/21/02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US RE
02/21/02 REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI RE
02/21/02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION RE
02/21/02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION" RE
02/21/02 REUTERS NEXT- PHILIP MORRIS CEO SAYS IN INVESTOR CONFERENCE IN FEB WE WILL HAVE QUALITY TIME TO EXPLAIN THE SOLVABLE OPPORTUNITIES TO INVESTORS WHAT VECTURA AND FERTIN WILL BRING TO PMI RE
02/21/02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - THOSE WORRIES THAT PEOPLE WILL LEAVE (BECAUSE OF DEAL) ARE WELL PUT BEHIND US RE
02/21/02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - NO SCIENTISTS FROM VECTURA HAVE LEFT CO BECAUSE OF PMI'S ACQUISITION RE
02/21/02 REUTERS NEXT- PHILIP MORRIS CEO ON VECTURA DEAL - "I DON’T THINK THERE IS ANYBODY WHO WILL DISAGREE THAT THIS IS A POSITIVELY DRIVEN TRANSFORMATION" RE
5 years 149
Extreme 149
176
10 years 59.1
Extreme 59.1
180.88
Manager TitleAgeSince
Chief Executive Officer - -
Chief Tech/Sci/R&D Officer - 01/06/2016
Corporate Secretary - 30/06/2025
Director TitleAgeSince
Director/Board Member 53 15/09/2023
Director/Board Member 57 30/06/2025
Date Insider Type Main position Quantity % Market Cap.
01/10/21 Fiscal year

Chief Executive Officer

13,11,395 0.2149%
01/10/21 Fiscal year 1,59,896 0.0262%
01/10/21 Fiscal year 19,28,114 0.3160%

Financials

2019 2020
Net sales 18Cr 16Cr 14Cr 13Cr 25Cr 1.72TCr 25Cr 172.73Cr 68Cr 841.26Cr 67Cr 65Cr 2.9TCr 19Cr 17Cr 15Cr 14Cr 27Cr 1.84TCr 27Cr 184.65Cr 72Cr 899.3Cr 72Cr 70Cr 3.1TCr
Net income -2.21Cr -1.94Cr -1.79Cr -1.65Cr -3.11Cr -213.11Cr -3.16Cr -21Cr -8.39Cr -104.27Cr -8.3Cr -8.12Cr -359.25Cr 12Cr 11Cr 9.92Cr 9.12Cr 17Cr 1.18TCr 17Cr 118.58Cr 46Cr 577.51Cr 46Cr 45Cr 1.99TCr
Net Debt -6.65Cr -5.83Cr -5.39Cr -4.96Cr -9.35Cr -641.27Cr -9.5Cr -64Cr -25Cr -313.76Cr -25Cr -24Cr -1.08TCr -7.44Cr -6.52Cr -6.03Cr -5.54Cr -10Cr -717.45Cr -11Cr -72Cr -28Cr -351.04Cr -28Cr -27Cr -1.21TCr
Logo Vectura Group
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.
Employees
-
Sector
-